Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset
Thorax2007Vol. 63(1), pp. 53–59
Citations Over TimeTop 10% of 2007 papers
Isabelle Tillie‐Leblond, Marie Wislez, Dominique Valeyre, Bruno Crestani, Antoine Rabbat, Dominique Israël‐Biet, Marc Humbert, Louis Jean Couderc, B. Wallaert, Jacques Cadranel
Abstract
Early testing for anti-synthetase antibodies, particularly anti-Jo-1, and creatine kinase determination are useful procedures in patients presenting with ILD. Treatment with corticosteroids and immunosuppressive drugs is required in most patients. At the end of the study, around two-thirds of patients had stable ILD while the other third had disease progression with respiratory insufficiency.
Related Papers
- → Interstitial lung diseases(2022)465 cited
- → Interstitial lung disease in polymyositis and dermatomyositis(2005)158 cited
- → Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting(2020)39 cited
- → Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A(2002)101 cited
- → Determining progression of scleroderma-related interstitial lung disease(2018)17 cited